AllCells News & Events

AllCells will be exhibiting at the 9th Annual Protein and Antibody Engineering Summit (PEGS) taking place in Boston, MA 4/29-5/3. Join us and other leading biotechnology companies, learn about our new bioservices....

AllCells will be joining other leading cancer research biotech organizations at the AACR (American Association for Cancer Research) Annual Meeting taking place April 6-10th in Washington DC. Visit Booth #1705 to meet with our associates and...

AllCells has launched our Bioservices homepage to complement our new division featuring immunoassays, stem cell assays, flow cytometry services, tissue culture services, protein analysis, and genotyping.
To read more on our blog: 

Today AllCells announced its new Bioservices launch. Please read the full news release on our Bioservices line for more information.

Join us in our backyard as San Francisco hosts the 2012 American Society for Cell Biology Annual Meeting. Visit Booth #1204 to meet several AllCells associates as we debut our new products/services for 2013 and win a chance at a prize! For more information see the official website for the conference here.

(EMERYVILLE, CA) November 20, 2012 - AllCells, LLC a leading global provider of human hematologic tissue, healthy & diseased primary cells, and cell-based assay services, today announced it has entered into a Distribution Agreement with Wako Pure Chemical Industries, Ltd. (Osaka, Japan), a leading global provider of laboratory chemicals, specialty chemicals, and diagnostic reagents. Under the agreement AllCells has granted Wako Pure Chemical Industries non-exclusive rights to distribute its products to Japan’s life science research community. Dr. Elaine Horibe Song, Senior Product Manager indicated “We are pleased to partner with Wako to provide researchers with access to more than 600 products and relevant clinical data from healthy and diseased hematologic tissue, such as bone marrow, peripheral blood, Leukopaks, and cord blood.” Dr. Jack Zhai, VP of Sales & Marketing added, “Wako’s large commercial network of direct sales, sub-dealers, and substantial ecommerce capabilities provides AllCells with greater access to a large number of end users including scientists within the academia/non-profit market segment.” AllCells’ President and Chief Executive, Jay Tong, M.D commented, “Japan’s drug discovery and pre-clinical development market are key application areas for AllCells’ products and services. Wako’s well-established market presence, broad selection of high quality laboratory chemicals and reagents, and comprehensive sales channels enhance our ability to better serve the needs of scientific researchers in Japan”. About AllCells, LLC AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells (healthy & diseased) which enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications in which in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce the time needed to isolate cells with guaranteed consistency, thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements. AllCells, LLC Media Contact: Wayne E. Vaz, 603 490 7992 Vice President, Corporate & Business Development wvaz@allcells.com

Leading Provider of Hematology-Based Products & Services to the Life Science Industry Ranked No. 2,420 of Fastest Growing Private Companies in U.S. Please read the full news release here.

EMERYVILLE, California – June 1, 2012 – AllCells, a leading provider of healthy & diseased hematological tissue, primary cell-based products, and services will be attending the 2012 Biotechnology Industry Organization (BIO) International Convention One-on-One Partnering™ program to be held Jun 18-21 in Boston, MA. Wayne Vaz – VP, Corporate & Business Development, Jack Zhai - VP, Marketing & Sales, and Elaine Horibe Song - Sr. Product Manager, will be available to meet at the Boston Convention & Exhibition Center to discuss the company’s capabilities, strategic partnership and collaboration interests. According to BIO, One-on-One Partnering™ has grown over the past 11 years to become biotech’s largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. This year BIO estimates that 4,000 companies will be participating in the One-on-One Partnering™ System including delegates from 65 countries with 25,000 meetings expected over 4 days. BIO Business Forum participants interested in learning more about AllCells or scheduling meetings to discuss partnering opportunities should log into BIO’s One-on-One Partnering™ program page at http://oneononepartnering.bio.org/BusinessForum2012/. Individuals not directly participating in the Business Forum who wish to meet AllCells company representatives may contact Wayne Vaz at wvaz@allcells.com to arrange an alternative meeting venue. BIO One-on-One Partnering is a trademark of the Biotechnology Industry Organization About AllCells, LLC AllCells (www.allcells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease, and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.

AllCells is proud to sponsor this year's American Association of Immunologists Annual Meeting. Visit our booth #204 to meet with several representatives about your research. For more information see the official website for the conference here.

Visit AllCells booth #1501 at the upcoming American Association for Cancer Research meeting in Chicago. Tell us about your research and win prizes! More info about the meeting here.

(EMERYVILLE, CA) February 3, 2012 - AllCells, LLC a global provider of human primary cells and related services, announced it has entered into a biomaterials license agreement with the WiCell Research Institute and Wisconsin Alumni Research Foundation (WARF). The agreement allows AllCells to cultivate the pluripotent cell lines derived from hematopoietic cancer cells obtained by the company. Under the agreement WiCell will distribute the pluripotent cell lines to stem cell researchers and WARF’s non-exclusive license allows AllCells to use the pluripotent cell lines for non-commercial research purposes. The pluripotent lines were developed by Dr. Igor Slukvin and his research team at the University of Wisconsin-Madison. “Induced pluripotent stem cell (iPSC) lines are emerging as an important platform technology for deriving specific biological cell types that would otherwise be difficult to source. These iPSC-derived cell types offer great potential for use as an enabling research tool for pre-clinical drug development,” said Dr. Jack Zhai, Vice President Marketing and Sales at AllCells and an alumnus of the University of Wisconsin-Madison. “AllCells supports WiCell’s goal of making these cell lines available as a tool for advancing scientific research. We will continue to look for opportunities to establish license, product and service supply agreements with leading life science companies.” “We are excited to add these new iPS cell lines to WiCell’s growing list of cell lines available through our Wisconsin International Stem Cell (WISC) Bank,” said Erik Forsberg, Ph.D., executive director of WiCell. “We look forward to working with AllCells and other organizations to offer pluripotent stem cell lines for research and clinical development.” About AllCells, LLC AllCells (www.allcells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications in which in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce the time needed to isolate cells with guaranteed consistency, thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements. About WiCell WiCell Research Institute is a Wisconsin nonprofit organization that was established in 1999 to advance stem cell research and development. WiCell distributes pluripotent stem cell lines through the Wisconsin International Stem Cell (WISC) Bank and provides comprehensive cytogenetic services (including karyotyping, FastFISH™ and array-based comparative genomic hybridization (aCGH)). WiCell also offers Quality Control testing services and clinical grade pluripotent cell lines to researchers worldwide. About WARF Since its founding in 1925 to manage a UW–Madison discovery that eventually eliminated the childhood disease rickets, WARF has been working with industry to transform university research into products that benefit society. As a private, nonprofit organization, WARF accomplishes its mission of supporting scientific research by patenting and licensing inventions arising from university discoveries. Since making its first grant of $1,200 in 1928, WARF has contributed more than $1 billion to UW–Madison through annual "margin of excellence'' grants and other funding. For more information, visit www.warf.org. AllCells, LLC Media Contact: Wayne E. Vaz, 603 490 7992 Vice President, Corporate & Business Development wvaz@allcells.com

Emeryville, CA (January 3, 2012) – AllCells, LLC announced that it has been granted a License for the Production of Biologics by the State of California Department of Public Health in accordance with Division 2, Chapter of the Health and Safety Code. This license enables AllCells to engage in broader business development opportunities involving the collection, processing, storage, or distribution of human hematological tissue and tissue derivatives. Together with the previously granted Tissue Bank License AllCells complies with laws and regulations covering the supply of products that support drug discovery, stem cell research, cell-based assay development, and a multitude of other important life science industry applications. AllCells is committed to providing its customers with high quality biological products and services in an ethical manner according to IRB-approved protocols, and in compliance with current government regulations. About AllCells, LLC AllCells (www.allcells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements. AllCells, LLC Media Contact: Wayne E. Vaz, 603 490 7992 Vice President, Corporate & Business Development wvaz@allcells.com

EMERYVILLE, Calif.--(BUSINESS WIRE)-- AllCells, LLC, a leading global provider of hematology and immunology based primary cells and related services for drug discovery, toxicology, stem cell research, and other life science applications today announced the appointment of its first Scientific Advisory Board (SAB). The new SAB members include: Linzhao Cheng, PhD - Professor of Medicine and a founding member of the Stem Cell Program in the Johns Hopkins Institute for Cell Engineering, JHU School of Medicine (JHUSOM), Baltimore, MD. He is also the Associate Director for Basic Research, Division of Hematology, and a faculty member in PhD Training Programs in Cellular & Molecular Medicine, Human Genetics and Immunology in JHUSOM. Dr. Cheng will serve as Chairman of AllCells’ SAB. Ronald Hoffman, MD - Professor of Medicine at the Mount Sinai School of Medicine, New York, NY, Co-Director, Myeloid Malignancy Program (MPP) of the Tisch Cancer Institute (TCI), Mount Sinai School of Medicine, Principal Investigator of the Myeloproliferative Research Consortium (MPD-RC) - a program project grant funded by the NCI, and a former President of the American Society of Hematology. Timothy C. Fong, PhD, MBA - Vice President, Technology and Product Development at Progenitor Cell Therapy (a NeoStem, Inc. company), Mountain View, CA. He is the former Technical Director, Cell Therapy, and Director of the BD Cell Therapy initiative at BD Biosciences, VP Research at Cellerant Therapeutics, and VP Discovery Research at Sangstat Medical Corp. AllCells’ President and Chief Executive, Jay Tong, MD, commented, “These outstanding scientific leaders together offer broad knowledge and expertise in the fields of hematology, immunology, cancer research, and stem cell science. Their contributions will be vitally important for shaping the future direction of AllCells’ products and services which serve the life science community.” “AllCells has experienced steady growth during the past several years and the newly created SAB is an important milestone in the company’s development. The SAB is expected to strengthen AllCells’ ability to identify and assess strategic opportunities that fit squarely with the company’s core competencies,” added Wayne Vaz, Vice President of Corporate Development. About AllCells, LLC AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements. .

Contacts

AllCells, LLC Wayne Vaz, 603-490-7992 Corporate & Business Development View full release

AllCells will be broadcasting a free webinar on December 1st, 9:00am - 10:00am PST and again December 5th, 5:00pm - 6:00pm PST titled "Leuko Pak 101: How leukapheresis products are best utilized in the lab". Join our team as we discuss leukapheresis, our Leuko Pak product line, and various related research applications. Learn and exchange information about this under-utilized source of, amongst other things, large quantities of cells that typically have lower yields. >>Official registration December 1st here >>Official registration December 5th here

AllCells will be represented at the upcoming, highly-anticipated  Stem Cells in Drug Discovery and Development conference taking place from November 2-3 in San Diego, CA. Stop by our booth to learn more about our products and services.Please visit the official conference website to learn more about this exciting event!

We will be presenting our new innovative custom projects and services at the International Society for Stem Cell Research meeting on June 15-18. Please stop by booth #325 to learn more. For more information on ISSCR, please visit www.isscr.org

Recently, AllCells research team joined Prof. Linzhao Cheng from John Hopkins University in a joint research effort in iPSC technology. The exciting results of the research has been published in Cell Research, Nature Publishing Group journal in January 2011. Download PDF

AllCells will be exhibiting at the upcoming Molecular Med Tri-Con 2011 (February 23-25) meeting taking place at the San Francisco Moscone Convention Center. For more information about the meeting, go to www.triconference.com

AllCells, LLC, a leading global provider of human primary cells and related services has announced an expanded range of primary adult stem cell products for in-vitro research use. A total of fifteen (15) new primary stem cell products are now available within the areas of Dental Mesenchymal stem cells, Cord Blood stem cells, Amniotic stem cells, and Placental stem cells. Read more here.

AllCells will be exhibiting at the upcoming American Society of Hematology Annual Meeting. Read more here.

AllCells is pleased to announce we will be attending the American Society of Hematology annual meeting, taking place in Orlando, FL in December. Visit our booth (#1365) for your chance to win a prize! More details will be revealed in the coming months. For more information on the American Society of Hematology, please visit www.hematology.org

AllCells will enlighten conference attendees with information about their stem cell products and services at the 8th annual ISSCR meeting. Read more here.

AllCells is pleased to announce our attendance in the 2010 ISSCR conference in San Francisco, CA. During the ISSCR, we will be higlighting our products and services to our stem cell research community. Visit us at booth #317. For more information regarding the ISSCR, please visit www.isscr.org

AllCells is excited to announce Hematopoietic cells from donors with blood related disease including Leukemia, Lymphoma, Myelodysplastic syndrome, Myeloproliferative disease and Multiple Myeloma. These cells allow researchers to understand what causes the disease in these cells and allow them to study how to eradicate the disease. Read more: AllCells announces hematopoietic disease cells for blood related disease research.

AllCells is pleased to announce our attendance at the 2010 American Association of Immunologists conference in Baltimore, MD. During the AAI, we will be higlighting our products and services to our cancer research community. We will be exhibit in booth #1203. For more information regarding the AAI, please visit www.aai.org